Rx Product News (April 2018)

APRIL 22, 2018

MORPHABOND ER
MANUFACTURED BY:
Daiichi-Sankyo
INDICATION: MorphaBond ER (morphine sulfate extended-release) is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
DOSAGE FORM: Extended-release tablets: 15, 30, 60, and 100 mg
FOR MORE INFORMATION: daiichisankyo.com


REBINYN
MANUFACTURED BY:
Novo Nordisk
INDICATION: Novo Nordisk said that Rebinyn Coagulation Factor IX (recombinant), GlycoPEGlated, has been made available to pharmacies. The FDA approved the drug in May 2017 for treating and controlling bleeding in adults and children.
DOSAGE FORM: Lyophilized powder for solution for intravenous injection
FOR MORE INFORMATION: rebinyn.com


ZYTIGA
MANUFACTURED BY:
Janssen Pharmaceutical Companies of Johnson & Johnson
INDICATION: The FDA has approved a new indication for abiraterone acetate (Zytiga, Janssen) in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer.
DOSAGE FORM: Film-coated tablet: 500 and 250 mg; uncoated tablet: 250 mg
FOR MORE INFORMATION: zytiga.com


QVAR REDIHALER
MANUFACTURED BY:
Teva Pharmaceutical Industries Ltd
INDICATION: Teva said that beclomethasone dipropionate HFA (QVAR RediHaler) Inhalation Aerosol is now commercially available to patients in both 40 and 80 mcg strengths by prescription in the United States. QVAR RediHaler is the first and only breath-actuated aerosol inhaled corticosteroid for the maintenance treatment of asthma as a prophylactic therapy in patients aged 4 years and older.
DOSAGE FORM: Breath-actuated inhalation aerosol: 40 or 80 mcg per actuation
FOR MORE INFORMATION: tevapharm.com

SHARE THIS
0